Business Context and Reporting Period
Company: Veeva Systems Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended July 31, 2026
Business Overview: Veeva is the leading provider of industry cloud solutions for the global life sciences industry, offering applications, agents, data, and consulting for research, development, quality, and commercialization functions. The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 31, 2026 | Six Months Ended July 31, 2026 |
|---|---|---|
| Total Revenues | $927,963 | $1,810,911 |
| Net Income | $273,429 | $534,365 |
| Diluted EPS | $1.66 | $3.22 |
| Operating Income | $275,018 | $548,130 |
| Gross Margin | 75% | 75% |
| Operating Cash Flow (6mo) | $1,365,825 | |
| Cash & Short-Term Investments | $7,242,947 (as of July 31, 2026) | |
| Debt | No long-term debt reported; liabilities consist primarily of deferred revenue and lease obligations. |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 18% year-over-year (YoY) for the quarter and 17% YoY for the six-month period. Subscription revenue grew 16% YoY, driven by R&D and Quality Solutions ($68M increase in Q2) and Commercial Solutions ($40M increase in Q2). Professional services revenue grew 24% YoY.
- Profitability: Net income increased 36% YoY for the quarter ($273.4M vs. $200.3M) and 25% YoY for the six months ($534.4M vs. $428.5M). Operating income rose 40% YoY for the quarter.
- Expense Management: General and Administrative (G&A) expenses decreased 26% YoY for the quarter, primarily due to the absence of a $31M litigation settlement charge incurred in the prior year. R&D and Sales & Marketing expenses increased due to higher employee compensation and headcount.
- Acquisition: On March 9, 2026, the company acquired Ostro (Rise Healthcare Tech, Inc.) for $90 million ($70M net of cash) to enhance AI-driven patient and doctor engagement capabilities.
- Share Repurchases: The company repurchased 2.66 million shares for approximately $467 million during the six months ended July 31, 2026, under a $2 billion program authorized in January 2026.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D and Quality Solutions to continue increasing as a percentage of total revenues. The company anticipates continued growth driven by expanding use by existing customers and annual inflation adjustments.
- Tax Environment: The effective tax rate decreased to 21.8% for the quarter (from 24.5% prior year) due to an increase in the foreign-derived deduction eligible income (FDDEI) deduction under the "One Big Beautiful Bill Act" (OBBBA).
- Key Risks:
- Competition: Intense competition from Salesforce, IQVIA, and others, particularly regarding the migration of customers from legacy Veeva CRM to Vault CRM.
- Third-Party Reliance: Dependence on Amazon Web Services and Salesforce for infrastructure; disruptions could impact service delivery.
- Regulatory & Geopolitical: Risks related to data privacy laws (GDPR, EU Data Act), AI regulations, and geopolitical conflicts (e.g., Middle East) affecting operations and customers.
- Customer Concentration: Top 10 customers accounted for 28% of total revenues in the prior fiscal year.
Investor Verification Checklist
- CRM Migration Progress: Verify the rate of customer migration from the legacy Salesforce-based Veeva CRM to the proprietary Vault CRM platform and any associated churn or delays.
- Deferred Revenue Trends: Analyze the $1.31 billion deferred revenue balance and the $200 million decrease in the six-month period to assess future revenue visibility.
- Share Repurchase Impact: Confirm the remaining $1.4 billion authorization under the buyback program and its impact on future liquidity and EPS.
- Acquisition Integration: Monitor the integration of Ostro and the realization of synergies from the $90 million acquisition.
- Tax Rate Sustainability: Evaluate the sustainability of the reduced effective tax rate driven by the OBBBA provisions and FDDEI deductions.